Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

NCT06533761 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

AML, Adult
MDS

Interventions

DRUG: Eganelisib
DRUG: Eganelisib in combination with cytarabine

Sponsor

Stelexis BioSciences